Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2010 - 2025)
Lifecore Biomedical, Inc. \De\ (LFCR) posted quarterly EBITDA Margin of 14.62% for Q2 2025, up 894.0% year-over-year from 1.47% in Q2 2024, and up 156.91% quarter-over-quarter from 25.68% in Q1 2025.
Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2010 - 2025) Analysis & Trends
Lifecore Biomedical, Inc. \De\'s EBITDA Margin history runs 16 years deep, the most recent figure standing at 14.62% for Q2 2025.
- In Q2 2025, EBITDA Margin rose 894.0% year-over-year to 14.62%; the TTM figure through May 2025 stood at 13.38% (down 649.0% YoY), while the FY2025 annual figure was 13.38%, down 649.0% from the prior year.
- EBITDA Margin for Q2 2025 stood at 14.62%, up from 25.68% in the prior quarter.
- The five-year high for EBITDA Margin was 14.62% in Q2 2025, with the low at 46.89% in Q3 2024.
- The 5-year median for EBITDA Margin is 14.28% (2021), against an average of 13.35%.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin jumped 2784 bps in 2021, then sank 3889 bps in 2022.
- Lifecore Biomedical, Inc. \De\'s EBITDA Margin stood at 14.41% in 2021, then slumped by 270 bps to 24.48% in 2022, then soared by 80 bps to 4.92% in 2023, then dropped by 22 bps to 6.02% in 2024, then jumped by 343 bps to 14.62% in 2025.
- Business Quant data shows LFCR's EBITDA Margin at 14.62% in Q2 2025, 25.68% in Q1 2025, and 6.02% in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| May 25, 2025 | 14.62% |
| Feb 23, 2025 | -25.68% |
| Nov 24, 2024 | -6.02% |
| Aug 25, 2024 | -46.89% |
| May 26, 2024 | 5.67% |
| Feb 25, 2024 | -2.51% |
| Nov 26, 2023 | -4.92% |
| Aug 27, 2023 | -35.13% |
| May 28, 2023 | -21.31% |
| Feb 26, 2023 | -24.61% |
| Nov 27, 2022 | -24.48% |
| Aug 28, 2022 | -13.80% |
| May 29, 2022 | -8.94% |
| Feb 27, 2022 | -27.36% |
| Nov 28, 2021 | 14.41% |
| Aug 29, 2021 | -18.91% |
| May 30, 2021 | -14.77% |
| Feb 28, 2021 | 0.26% |
| Nov 29, 2020 | 5.78% |
| Aug 30, 2020 | -46.76% |